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Introduction
Under basal conditions, the majority of hematopoietic stem and 
progenitor cells (HSPCs) reside in specialized environments with-
in the bone marrow termed the hematopoietic niche. The majority 
of hematopoietic stem cells (HSCs) are perivascular, where they 
are in close contact with endothelial cells and CXCL12- expressing 
mesenchymal stromal cells (1–4). HSPCs are mobilized into the 
circulation in response to a number of stimuli, including hema-
topoietic growth factors, myeloablative agents, and environmen-
tal stresses such as infection. Mobilized HSPCs have become the 
preferred cellular source for reconstitution of the bone marrow 
following myeloablative therapy because of their potency, pre-
dictability, and safety. Granulocyte–colony stimulating factor 
(G-CSF), a hematopoietic growth factor, is the mobilizing agent 
most commonly used in a clinical setting.
There is strong evidence that most mobilizing agents, includ-
ing G-CSF, induce HSPC egress by altering the bone marrow 
microenvironment. HSPC mobilization by G-CSF is primarily 
mediated by suppressing CXCL12 expression in bone marrow 
mesenchymal stromal cells, the major ligand for CXCR4 (5–7). We 
previously showed that G-CSF signaling in monocytic cells in the 
bone marrow is sufficient to downregulate CXCL12 expression and 
induce robust HSPC mobilization (8). Consistent with this find-
ing, 2 groups showed that ablation of bone marrow macrophages 
results in HSPC mobilization (9, 10). Together, these observations 
suggest that bone marrow macrophages play an important role in 
regulating HSPC trafficking from the bone marrow, although the 
signals that mediate this response are unknown.
Dendritic cells (DCs) are professional antigen presenting 
cells that are present in most tissues. In addition to antigen pre-
sentation, DCs contribute to immune cell activation through the 
secretion of cytokines and chemokines. DCs display considerable 
phenotypic and functional heterogeneity. DCs can be broadly 
classified, based on morphology, cell surface receptor expression, 
and developmental requirements, into 3 major groups: plasmacyt-
oid DCs, type 1 conventional DCs (cDC1s), and type 2 convention-
al DCs (cDC2s). Expression profiles of conventional DCs (cDCs) 
vary significantly based on tissue type, suggesting that cDCs 
may play distinct roles in different tissue (11). Single-cell RNA 
sequencing suggests that there may be considerable heterogene-
ity of DCs even within a single tissue type. For example, single-cell 
RNA sequencing identified at least 4 discrete cDC populations in 
human blood (12).
Prior studies have identified a resident population of DCs in 
the bone marrow and provided evidence that these cells promote 
the survival of recirculating mature B cells and regulate memory T 
cells in the bone marrow (13, 14). Whether these cells regulate oth-
er aspects of hematopoiesis is currently unknown. In this study, we 
provide evidence that bone marrow DCs are a functionally distinct 
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Figure 1. The majority of bone marrow dendritic cells have a cDC2-like phenotype, are enriched in the perivascular region, and have a unique RNA 
expression profile. (A) Representative flow plots showing the gating strategy used to identify bone marrow monocytes, macrophages, and DCs using 
Cx3cr1CXgfp/+ mice. (B) The gated monocyte, macrophage, and DC populations were profiled for expression of the indicated lineage markers. FMO, fluores-
cence minus one control. (C) Representative photomicrographs of femur sections from Cx3cr1gfp/+ mice. Top: CX3CR1-GFP (green) and MCH-II (red). Middle 
and bottom: CX3CR1-GFP (green), Sca1+ arterioles (red), VE-cadherin+ venous sinusoids and arterioles (white). Yellow arrows indicate DCs. Counterstaining 
with DAPI highlights nuclei (blue). (D, E) Quantification of the distance from DCs to the nearest venous sinusoid (D) or arteriole (E) (data pooled from n = 3 
mice). (F) Representative flow plot showing expression of 2 murine cDC markers, XCR1 for cDC1 and CD11b for cDC2. Data are gated on Gr-1– B220– MHC-IIhi 
CD11chi DCs. (G) Representative flow plot showing the expression of 2 human cDC markers, CD141 for cDC1 and CD1c for cDC2, on human bone marrow 
cDCs (n = 3 donors). Data are gated on lineage– CD45+ CD14– CD13+ CD33+ CD11c+ HLA-DR+ DCs. (H) Bone marrow DCs were sorted from Cx3cr1gfp/+ mice as 
Gr-1– B220– MHC-IIhi CD11chi CX3CR1-GFPhi cells. Heatmap comparing the expression of all chemokines and their receptors expressed in murine BM DCs and 
spleen (Sp) cDC2s (Gene Expression Omnibus database, accession no. GSE110789) (49). Data are mean ± SEM.
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expression for chemokines, chemokine receptors, and certain DC 
marker genes were strikingly different, suggesting that bone marrow 
DCs may represent a unique dendritic cell population with distinct 
functional properties (Figure 1H and Supplemental Table 1).
Ablation of bone marrow DCs induces a loss of macrophages and 
HSPC mobilization. To assess their functional importance, bone 
marrow DCs were ablated using Zbtb46dtr mice. Recent studies 
have identified ZBTB46 as a transcription factor that is expressed 
in cDCs but not in plasmacytoid DCs (pDCs), macrophages, or 
other myeloid or lymphoid cells (23, 24). To confirm the spec-
ificity of Zbtb46 expression in bone marrow DCs, we analyzed 
Zbtb46gfp mice, in which GFP is knocked into the Zbtb46 locus (24). 
As expected, ZBTB46-GFP was expressed at high levels in bone 
marrow DCs, but not in bone marrow macrophages or monocytes 
(Figure 2A). Since endothelial cells also express Zbtb46 (24), we 
transplanted Zbtb46dtr bone marrow into irradiated WT recipients 
to restrict Zbtb46dtr to the hematopoietic lineage. Diphtheria toxin 
(DT) treatment of Zbtb46dtr bone marrow chimeras resulted in a 
marked loss of bone marrow DCs (Figure 2B and Supplemental 
Figure 2A). Surprisingly, we also observed a loss of bone marrow 
macrophages (Figure 2B). However, the macrophage loss was 
delayed compared with cDC loss, raising the possibility that the 
decrease in macrophages is non–cell autonomous and second-
ary to cDC ablation. To test this possibility, we generated mixed 
bone marrow chimeras containing both WT and Zbtb46dtr hema-
topoietic cells. As expected, DT treatment resulted in the loss of 
Zbtb46dtr-derived but not WT-derived bone marrow cDCs (Figure 
2C). In contrast, DT treatment resulted in decreases of both WT- 
and Zbtb46dtr-derived bone marrow macrophages (Figure 2D). 
Of note, DT treatment of WT mice did not result in a decrease in 
cDCs or macrophages in the bone marrow, nor did it induce HSPC 
mobilization (Supplemental Figure 2, B–E). Collectively, these 
data strongly suggest that cDC ablation results in a secondary, 
non–cell autonomous, loss of bone marrow macrophages.
We next assessed the impact of cDC ablation on HSPC traf-
ficking. Ablation of bone marrow macrophages has been reported 
to alter the bone marrow niche and induce HSPC mobilization (9, 
10). Thus, to determine whether bone marrow DCs have a macro-
phage-independent role in the regulation of HSPC trafficking, we 
compared HSPC mobilization after DT treatment in Zbtb46dtr, 
Cd169dtr, or Zbtb46dtr × Cd169dtr bone marrow chimeras. A prior 
study showed that Cd169dtr efficiently ablates bone marrow macro-
phages and results in modest HSPC mobilization (9). Treatment of 
Zbtb46dtr bone marrow chimeras with DT resulted in modest mobi-
lization of CFU-C, c-kit+ Sca1+ lineage– (KSL), and CD150+ CD48– 
KSL (KSL-SLAM) cells (Figure 2, E–H), but did not affect HSPCs in 
the bone marrow (Supplemental Figure 3, A–C). Of note, DT treat-
ment of Zbtb46dtr bone marrow chimeras did not result in an acute 
increase in blood or bone marrow neutrophils, or changes in bone 
marrow or spleen cellularity, suggesting that cDC ablation is not 
inducing systemic inflammation (Supplemental Figure 3, D–G). 
Importantly, the magnitude of HSPC mobilization in Zbtb46dtr 
bone marrow chimeras was significantly greater than that 
observed in Cd169dtr bone marrow chimeras but similar to that 
seen in the Zbtb46dtr × Cd169dtr bone marrow chimeras (Figure 2, 
E–H), suggesting that cDC ablation induces HSPC mobilization, at 
least in part, in a macrophage-independent fashion.
population of dendritic cells that have evolved to regulate hema-
topoiesis. We show that bone marrow DCs regulate endothelial 
cell function, in part, through CXCR2 signaling, resulting in HSPC 
mobilization and a loss of bone marrow macrophages. These find-
ings establish bone marrow DCs as a new cellular component of 
the perivascular stem cell niche in both mice and humans.
Results
Bone marrow DCs are enriched in the perivascular region in mice 
and have a distinct phenotype. To better characterize bone mar-
row DCs, we developed a multicolor flow cytometry to analyze 
myeloid cell populations in Cx3cr1gfp/+ mice, which express high 
levels of green fluorescent protein (GFP) in monocytes and bone 
marrow DCs, but not in bone marrow macrophages (9, 15, 16). 
Monocytes were identified as CX3CR1-GFPhi MHC-IIlo Gr-1lo 
B220–/CD19– cells (Figure 1A), and, consistent with a prior 
study, expressed F4/80 (17) but were mostly negative for CD11c 
and CD169 (Figure 1B). Bone marrow macrophages were iden-
tified as CX3CR1-GFPlo MHC-II+ Gr-1lo B220–/CD19– cells and 
expressed CD169 and F4/80, but little CD11c (Figure 1, A and 
B). Finally, bone marrow DCs were identified as CX3CR1-GFPhi 
and MHC-IIhi Gr-1lo B220–/CD19– cells. As expected, bone mar-
row DCs expressed a high level of CD11c and F4/80 (13), but a 
low level of CD169 (Figure 1, A and B). DCs represent 0.048% 
± 0.017% of nucleated cells in mouse bone marrow compared 
with 0.096% ± 0.047% for macrophages (n = 11 mice). A prior 
study showed that bone marrow DCs are perivascular, although 
this study did not distinguish between venous sinusoids and 
arterioles (13). We show that CX3CR1-GFPhi and MHC-IIhi DCs 
all have a stellate morphology (Figure 1C), enabling the identifi-
cation of DCs as CX3CR1-GFPhi stellate cells. We found that the 
great majority of these cells in the bone marrow are perivascular 
(Figure 1C), with approximately 90% of cells within 10 ?m of a 
venous sinusoid or arteriole (Figure 1, D and E).
The high level of CD11c expression and stellate morphology 
of bone marrow DCs are consistent with cDCs (18, 19). To further 
characterize bone marrow DCs, we measured expression of XCR1 
and CD11b, which are selectively expressed on cDC1s and cDC2s, 
respectively (20). For these experiments, cDCs were identified as 
Gr-1– B220– MHC-IIhi CD11chi cells. Nearly all of the DCs express 
CD11b but not XCR1, suggesting that the majority of murine bone 
marrow DCs are cDC2 cells (Figure 1F). Of note, consistent with a 
prior study (21), we observed that murine BM cDC2 cells express a 
higher level of CX3CR1-GFP than cDC1 cells (Supplemental Figure 
1A; supplemental material available online with this article; https://
doi.org/10.1172/JCI124829DS1). We next examined bone marrow 
from healthy donors to determine whether DCs also are present in 
human bone marrow. Human bone marrow DCs were identified as 
lineage– CD45+ CD14– CD13+ CD33+ CD11c+ HLA-DR+ cells (Supple-
mental Figure 1B). Indeed, the percentage of DCs in human bone 
marrow (0.082% ± 0.025%, n = 3 donors) is similar to that seen in 
murine bone marrow. Moreover, the majority of DCs in human bone 
marrow express CD1c but not CD141, and do not express CD45RA, 
consistent with a mature cDC2 phenotype (Figure 1G, and Supple-
mental Figure 1B) (20, 22). RNA expression profiling was performed 
on sorted murine bone marrow DCs and compared with prior data 
generated using splenic cDC2s. Surprisingly, the patterns of gene 
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ment of Cd11cdtr bone marrow chimeras resulted in the efficient 
ablation of DCs and a delayed loss of macrophages in the bone 
marrow (Figure 2I). Treatment of Cd11cdtr bone marrow chimeras 
with DT did not affect the number of HSPCs in the bone marrow 
(Figure 2J and Supplemental Figure 3I), but resulted in a modest 
mobilization of CFU-Cs and KSL cells (Figure 2, K and L, and Sup-
plemental Figure 3J). The similar magnitude of bone marrow DC 
Zbtb46 is expressed in a subset of erythroid precursors (24). 
Indeed, DT treatment of Zbtb46dtr bone marrow chimeras result-
ed in a modest, but significant, decrease in basophilic erythro-
blasts, but not in later erythroid precursors (Supplemental Figure 
3H) (25). Thus, we repeated the HSPC mobilization studies using 
Cd11cdtr mice, a mouse model of cDC ablation that does not target 
erythroid precursors (26). Similar to the Zbtb46dtr mice, DT treat-
Figure 2. Bone marrow DC ablation induces a loss of macrophages and HSPC mobilization. (A) Expression of GFP in bone marrow monocytes (Gr-1lo B220– 
CD115+ cells), macrophages (Gr-1lo B220– MHC-II+ F4/80+ cells), and DCs (Gr-1lo B220– MHC-IIhi CD11chi cells) from Zbtb46gfp mice is shown. FMO, fluorescence 
minus one control. (B) Zbtb46dtr bone marrow chimeras were treated with DT for 1 day (n = 5 mice), 2 days (n = 5 mice), 6 days (n = 12 mice), or with PBS 
(day 0) (n = 11 mice), and BM DCs and macrophages were quantified. (C, D) Mixed bone marrow chimeras containing WT and Zbtb46dtr cells were treated 
with PBS or DT for 6 days, and the number of DCs (C) and macrophages (D) in the bone marrow that were derived from WT or Zbtb46dtr (Zbtb46-DTR) cells 
were quantified (n = 5 mice per cohort). (E–H) Zbtb46dtr, CD169dtr (CD169-DTR), and CD169dtr × Zbtb46dtr (CD169/Zbtb46-DTR) chimeras were treated with 
PBS or DT for 6 days, and the number of lineage- sca1+ c-kit+ (KSL) cells (E) (n = 11, 15, 18, 16 mice) or CD150+ CD48– KSL (KSL-SLAM) cells in the spleen (F) (n 
= 8, 10, 14, 13 mice) and the number of colony-forming cells (CFU-C) in spleen (G) (n = 14, 13, 12, 15 mice) or blood (H) (n = 15, 14, 12, 16 mice) were quantified. 
(I) CD11cdtr chimeras were treated with DT for 1 day (n = 3 mice), 6 days (n = 10 mice), or with PBS (n = 10 mice), and BM DCs and macrophages were quanti-
fied by flow cytometry. (J–L) CD11cdtr bone marrow chimeras were treated with saline or diphtheria toxin (DT) for 6 days, and the number of CFU-C in bone 
marrow (J), spleen (K), and blood (L) was quantified (n = 10 mice per cohort). Data are mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 
compared with PBS-treated or day 0 mice. Significance was determined using an ANOVA with Tukey’s Honest Significant Difference post hoc analysis for 
C, E–H, a 2-way ANOVA for B, I, or an unpaired Student’s t test for J–L.
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imaging of bone sections of Cx3cr1gfp/+ mice 
(Supplemental Figure 4). Modest cDC 
mobilization also was observed after treat-
ment with AMD3100, a CXCR4 antagonist 
(Supplemental Figure 5). Compared with 
splenic cDC2s, bone marrow cDCs express 
a higher level of Csf3r, which encodes for 
the G-CSF receptor (Supplemental Table 1). 
To assess the contribution of G-CSF sig-
naling in cDCs to HSPC mobilization, 
we characterized G-CSF–induced HSPC 
mobilization in Zbtb46dtr bone marrow 
chimeras after cDC ablation. As expected, 
both G-CSF and cDC ablation resulted in a 
significant decrease in bone marrow cDCs 
and macrophages, with the lowest levels of 
these cells observed after combined G-CSF 
and cDC ablation (Figure 3, B and C). Abla-
tion of cDCs alone induced modest HSPC 
mobilization compared with G-CSF (Fig-
ure 3, D and E). However, the combina-
tion of cDC ablation and G-CSF treatment 
resulted in synergistic HSPC mobilization 
that was approximately 3-fold greater than 
that observed with G-CSF alone.
Ablation of bone marrow DCs induces 
endothelial cell expansion and increased vas-
cular permeability in the bone marrow. The 
close physical association of bone marrow 
DCs with sinusoidal endothelium, the site where most HSPC trans-
migration is thought to occur, prompted us to examine endothelial 
cell function following cDC ablation. We first assessed bone mar-
row vascular permeability, since it has been reported to positively 
affect HSPC mobilization in the bone marrow (27–29). Fluores-
cein-conjugated bovine serum albumin (FITC-BSA) was injected 
intravenously into Zbtb46dtr bone marrow chimeras following DT 
treatment. Mice were harvested after 15 minutes and immunos-
taining of femur sections was performed to quantify extravascular 
and intravascular FITC-BSA, as previously described (Figure 4A) 
(30). A modest but significant increase in vascular permeability 
was observed after 6 days of DT treatment (Figure 4C). We also 
ablation and HSPC mobilization in the Zbtb46dtr and Cd11cdtr chi-
meras strongly suggests that it is the loss of DCs that is responsible 
for HSPC mobilization in these mice.
Ablation of bone marrow DCs synergizes with G-CSF to mobilize 
HSPCs. We previously showed that G-CSF treatment is associated 
with a marked decline of monocytes in the bone marrow (8). Using 
our multicolor flow assay, we quantified cDCs in the bone mar-
row, peripheral blood, and spleen at baseline and following G-CSF 
treatment (Figure 3A). G-CSF treatment is associated with a 6.8-
fold decrease in cDCs in the bone marrow, while they are mod-
estly increased in the blood, suggesting that cDCs are mobilized 
by G-CSF. The decrease in bone marrow cDCs was confirmed by 
Figure 3. Bone marrow DC ablation synergizes 
with G-CSF to mobilize HSPCs. (A) Mice were 
treated with 250 ?g/kg G-CSF daily for 5 days. 
Shown are the number of cDCs in the bone mar-
row, blood, and spleen (n = 5, 4, 4 and 6 mice per 
time point). (B–E) Mice were treated with saline 
alone (PBS), G-CSF for 5 days, or the combina-
tion of DT and G-CSF for 5 days (n = 8 mice per 
cohort). The number of cDCs (B) and macro-
phages (C) in the bone marrow is shown. The 
number of KSL (D) or CFU-C (E) in bone marrow, 
blood, and spleen are shown. Data are mean ± 
SEM. *P < 0.05; **P < 0.0; ***P < 0.001; ****P 
< 0.0001 compared with saline-treated mice. 
Significance was determined using a 2-way 
ANOVA for A or an ANOVA with Tukey’s Honest 
Significant Difference post hoc analysis for B–E.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
2 9 2 5jci.org   Volume 129   Number 7   July 2019
observed a significant expansion of vascular endothelial cells by 
immunostaining (Figure 4, B and D) and flow cytometry (Figure 
4E) after cDC ablation. To further characterize alterations in the 
bone marrow vasculature, sinusoidal (lineage– CD31+ Sca1–) and 
arteriolar (lineage– CD31+ Sca1+) endothelial cells were flow sort-
ed from Zbtb46dtr bone marrow chimeras 1 day after DT treat-
ment, a time when bone marrow DCs, but not macrophages, are 
decreased in the bone marrow (Supplemental Figure 6A). RNA 
expression profiling was performed on the sorted populations. 
Principal component analysis (PCA) showed that sinusoidal but 
not arteriolar endothelial cells clustered based on cDC ablation 
(Supplemental Figure 6, B and C). To better characterize tran-
scriptional changes associated with cDC ablation, we performed 
RNA sequencing on sorted bone marrow sinusoidal endothelial 
cells. The data were analyzed using t-distributed stochastic neigh-
bor embedding (t-SNE) and, again, showed that cells clustered 
based on cDC ablation (Figure 5A). A total of 635 differentially 
expressed genes (> 5-fold difference and FDR < 0.02) were identi-
fied (Supplemental Table 2). Gene set enrichment analysis (GSEA) 
was performed and the top hit was related to chemokine/cytokine 
activation (Figure 5B). GSEA also suggested increased angiogene-
sis (Figure 5C), which is consistent with the modest expansion of 
vascular endothelial cells seen after cDC ablation. Collectively, 
these data show that cDC ablation results in vascular remodeling 
in the bone marrow, including modest angiogenesis and increased 
vascular permeability.
Ablation of bone marrow DCs may regulate HSPC trafficking par-
tially through activation of sinusoidal CXCR2 signaling. Among the 
most highly induced genes in sinusoidal endothelial cells following 
cDC ablation are certain chemokine receptors, including CCR1, 
CCR2, and CXCR2 (Figure 5D). CXCR2 is of particular interest, 
since prior studies have suggested that CXCR2 activation induces 
vascular permeability and HSPC mobilization (29, 31–33). We per-
formed real-time quantitative PCR on whole bone marrow RNA 
from Zbtb46dtr bone marrow chimeras following DT treatment to 
measure the expression of CXCL1 (KC) and CXCL2 (Gro-?), the 
Figure 4. Bone marrow DC ablation induces vascular endothelium permeability and expansion in the bone marrow. (A, B) Representative photomi-
crographs of femur sections from Zbtb46dtr bone marrow chimeras treated with PBS (left), 1 day of DT (1D-DT, middle) or 6 days of DT (6D-DT, right). (A) 
FITC-conjugated bovine serum albumin (BSA) was injected intravenously into mice 15 minutes before sacrifice. Sections were imaged for FITC-BSA (green) 
and VE-cadherin+/CD31+ endothelial cells (red). (B) Sections were imaged for VE-cadherin+/CD31+ endothelial cells (red) and counterstained with DAPI to 
highlight nuclei (blue). Original magnification, ×200. (C) The ratio of extravascular FITC-BSA to intravascular FITC-BSA was quantified and normalized 
to the PBS-treated cohort (n = 9, 8, 7 mice). (D, E) Histomorphometry (D) (n = 9, 8, 7 mice) or flow cytometry (E) (n = 4 or 6 mice) was used to quantify 
endothelium or endothelial cells in the bone marrow; endothelial cells were identified by flow cytometry as lineage– (CD45, Ter119, Gr-1) CD31+ cells. Data 
are mean ± SEM. *P < 0.05; **P < 0.01 compared with PBS-treated mice. Significance was determined using an ANOVA with Tukey’s Honest Significant 
Difference post hoc analysis for C and D, or an unpaired Student’s t test for E.
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principal ligands for CXCR2. RNA expression of both ligands was 
induced 3- to 4-fold in the bone marrow following cDC ablation 
(Figure 5, E and F). To directly test the effect of CXCR2 activation 
on endothelial cells, we performed transwell experiments using a 
human umbilical vein endothelial cell (HUVEC) monolayer (Figure 
6A). Vascular permeability, as measured by Evans blue passage into 
the bottom chamber was modestly, but significantly, increased by 
treatment with recombinant CXCL1 (Figure 6B). Likewise, CXCL1 
treatment increased the migration of human CD34+ cells through a 
HUVEC monolayer (Figure 6C). To assess the impact of endothe-
lial CXCR2 signaling in vivo, we transplanted Zbtb46dtr bone mar-
row into irradiated Cxcr2–/– recipients, thereby restricting the loss of 
CXCR2 signaling to endothelial cells and other stromal cells. Com-
pared with WT recipients, mobilization of KSL cells, KSL-SLAM 
cells, and CFU-Cs was significantly reduced in Cxcr2–/– recipients 
following cDC ablation (Figure 6, G, I, K, L and Supplemental Fig-
ure 7). Of note, cDC ablation in Cxcr2–/– recipients did not alter bone 
marrow or spleen cellularity, or HSPC numbers in the bone marrow 
(Figure 6, D–F, H, and J). Collectively, these data suggest that cDC 
ablation induces HSPC mobilization, in part, through CXCR2 acti-
vation in bone marrow sinusoidal endothelial cells.
Discussion
Consistent with a prior study by Sapoznikov and colleagues, 
we identified a resident population of DCs that localize to both 
venous sinusoids and arterioles in the bone marrow (13). The 
majority of bone marrow DCs are CD11b+ and XCR1–, classify-
ing them as cDC2-like cells. We identified a similar population 
of cDC2-like cells in human bone marrow. Several recent studies 
using single-cell analysis platforms show that there is considerable 
heterogeneity within the DC population, suggesting that current 
classification schemes may need to be expanded (22, 34–36). Our 
RNA expression profiling data suggest that bone marrow cDCs 
have a distinct pattern of gene expression. For instance, while 
certain cDC2 genes are highly expressed in bone marrow cDC2 
cells, such as Cx3cr1 and Fcgr1, certain cDC1 genes are also highly 
expressed, such as Irf8 and Clec9a (Supplemental Table 1). There 
also is considerable heterogeneity in the expression of chemokine, 
cytokine, and pattern recognition receptors in cDC2 cells from 
different tissues, which contributes to their functional diversity 
(11). Indeed, striking differences in chemokine receptor and toll-
like receptor expression were observed between splenic cDC2s to 
bone marrow cDC2s, with bone marrow cDC2s typically showing 
Figure 5. Ablation of bone marrow DCs activates sinusoidal endothelial cells. (A) Sinusoidal endothelial cells were sorted from Zbtb46dtr bone marrow 
chimeras treated with PBS or DT (1 day) and RNA-sequencing was performed. t-SNE analysis of PBS- (n = 4 mice) and DT-treated mice (n = 3 mice). (B, 
C) Gene set enrichment analysis (GSEA). (D) Fragments per kilobase (FPKM) values for all expressed chemokine receptors in sinusoidal endothelial cells. 
*False discovery rate < 0.05. Significance was determined using the Partek gene-specific analysis (GSA) algorithm. (E, F) Expression of CXCL1 (E) and 
CXCL2 (F) mRNA relative to ?-actin mRNA in the bone marrow of Zbtb46dtr chimeras following treatment with PBS (n = 6 mice) or DT for 1 day (1D-DT, n = 5 
mice) or 6 days (6D-DT, n = 5 mice). Data are mean ± SEM. ***P < 0.001 compared with PBS-treated mice. Significance was determined using ANOVA with 
Tukey’s Honest Significant Difference post hoc analysis for E and F.
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Figure 6. CXCR2 signaling contributes to HSPC mobilization following bone marrow DC ablation. (A–C) Human umbilical vein endothelial cells 
(HUVECs) cultured in a transwell to establish a monolayer were treated with PBS or CXCL1. (B) Relative amount of Evans blue dye in the lower chamber 
after 1 hour of CXCL1; data are normalized to PBS-treated samples (n = 5 or 6 mice). (C) Human bone marrow CD34+ cells were seeded on the HUVEC 
monolayer and treated with CXCL1 for 24 hours; the lower chamber contained 100 ng/ml CXCL12. Shown is the percentage of CD34+ cells that migrated 
to the lower chamber (n = 11–12 replicates). (D–L) Bone marrow cells from Zbtb46dtr mice were transplanted into irradiated WT or Cxcr2–/– recipients. 
Eight weeks after transplantation, mice were treated with PBS or DT for 6 days. Total cellularity of bone marrow (D) and spleen (E), the number of KSL 
cells in bone marrow (F) and spleen (G), the number of KSL-SLAM cells in bone marrow (H) and spleen (I), and the number of CFU-Cs in bone marrow 
(J), spleen (K), and blood (L) is shown (n = 6 per cohort). The WT recipient data are the same as shown in Figure 2. Data are mean ± SEM. *P < 0.05; **P 
< 0.01; ****P < 0.0001 compared with the PBS-treated group, unless otherwise specified. Significance was determined using an unpaired Student’s t 
test for B and C, or ANOVA with Tukey’s Honest Significant Difference post hoc analysis for D–L.
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will require further study. Treatment with CXCL1 induces vas-
cular permeability and transendothelial migration of HSPCs in 
vitro. Moreover, HSPC mobilization following cDC ablation is 
attenuated in mice lacking endothelial CXCR2 expression. These 
observations are consistent with a report by Hoggatt and col-
leagues showing that treatment with a CXCR2 agonist induces 
bone marrow vascular permeability and HSPC mobilization (29). 
It is also consistent with a companion paper by Karpova and col-
leagues showing that CXCR2 agonist–induced HSPC mobilization 
is dependent, in part, on CXCR2 signaling in endothelial cells (41). 
However, in the Zbtb46dtr Cxcr2–/– chimeras, CXCR2 expression is 
abrogated in all bone marrow stromal cells, raising the possibility 
that CXCR2 signaling in nonendothelial stromal cells contributes 
to HSPC mobilization. The residual HSPC mobilization in Cxcr2–/– 
recipients also suggests that there are non–CXCR2-dependent 
mechanisms that contribute to HSPC mobilization following cDC 
ablation. These mechanisms will require further investigation, 
but it is noteworthy that CCR1 and CCR2 are highly induced on 
sinusoidal endothelial cells following cDC ablation, and signaling 
from both of these receptors has been implicated in the regulation 
of endothelial cell function (42–44).
In summary, these data show that bone marrow DCs are an 
important cellular component of the perivascular hematopoietic 
niche. Their perivascular location and high expression of certain 
chemokine and pattern recognition receptors suggest that bone 
marrow DCs may play an important role in sensing and regulating 
the hematopoietic response to microbes and inflammatory signals.
Methods
Mice. The Cxcr1gfp/+ mice were a gift from David Littmann (New 
York University School of Medicine) (15). Zbtb46dtr (B6(Cg)- 
Zbtb46tm1(HBEGF)Mnz/J), Zbtb46gfp (129S-Zbtb46tm1Kmm/J), and Cxcr2–/– 
(C.129S2(B6)-Cxcr2tm1Mwm/J) mice were obtained from The Jackson 
Laboratory. Cd169dtr mice were a gift from Y. Obata (Riken BioRe-
source Center, Ibaraki, Japan) (45, 46). Cd169dtr mice were bred with 
Zbtb46dtr mice to generate Cd169dtr × Zbtb46dtr mice. Sex- and age-
matched mice were used in all experiments. All mice were inbred 
on a C57BL/6 background except Zbtb46gfp mice, which were on a 
mixed C57BL/6 and 129 SvEv background. The number of animals 
used per experiment is stated in the figure legends. Mice were main-
tained under SPF conditions, and all experimental procedures were 
performed according to methods approved by the Animal Studies 
Committee at Washington University.
Generation of bone marrow chimeras. Six- to eight-week-old WT 
Ly5.1/Ly5.2 recipient mice were irradiated with two 600 cGy doses, 
6 hours apart. Two million donor bone marrow cells were then retro- 
orbitally injected. Mice were placed on prophylactic antibiotics (tri-
methoprim-sulfamethoxazole) for 2 weeks following the first dose of 
irradiation. Mice were analyzed 8 weeks after transplantation.
Diphtheria toxin, G-CSF, and AMD3100 administration. Diphthe-
ria toxin (D0564, MilliporeSigma) was diluted in PBS containing 0.1% 
low-endotoxin BSA and administered intraperitoneally at a dose of 200 
ng/mouse/day for up to 6 days. G-CSF (neupogen, Amgen) was diluted 
in sterile PBC containing 0.1% low-endotoxin BSA and administered 
subcutaneously at a dose of 250 ?g/kg/day for 5 days. AMD3100 (Mil-
liporeSigma) was diluted in sterile PBS containing 0.1% low-endotoxin 
BSA and administered subcutaneously at a dose of 5 mg/kg.
higher expression. Collectively, these data suggest that bone mar-
row cDC2s may represent a unique dendritic cell population that 
has evolved to perform specialized functions.
We show that cDC ablation using either Zbtb46dtr or Cd11cdtr 
transgenic mice results in a loss of bone marrow macrophages 
and mobilization of HSPCs. Analysis of Zbtb46dtr bone marrow 
chimeras establishes that the macrophage loss is non–cell auton-
omous. The mechanism(s) by which cDCs regulate bone marrow 
macrophages is uncertain and will require further study. Howev-
er, it is noteworthy that bone marrow DCs express high levels of 
CCL6 (Figure 1H), which is known to regulate the migration and 
activation of macrophages (16). A prior study showed that abla-
tion of CD169+ macrophages induces modest HSPC mobilization 
(9). Indeed, we observed weak HSPC mobilization in our Cd169dtr 
bone marrow chimeras following macrophage ablation. However, 
HSPC mobilization was significantly greater after cDC ablation, 
and no significant increase in HSPC mobilization was observed 
with combined macrophage and cDC ablation compared with 
cDC ablation alone. These data suggest that bone marrow DCs 
regulate HSPC trafficking in a macrophage-independent fashion.
We previously reported that G-CSF signaling in monocytic- 
lineage cells is sufficient to mediate G-CSF–induced HSPC mobili-
zation (8). Within the monocytic-lineage cell population, the G-CSF 
receptor is expressed on monocytes, macrophages, and, based on 
our RNA expression data, bone marrow cDCs. Here, we show that 
cDC ablation synergizes with G-CSF to mobilize HSPCs, demon-
strating that G-CSF signaling in cDCs is not required for HSPC 
mobilization. A prior study showed that Gro-?, a CXCR2 ligand, 
synergizes with G-CSF to induce HSPC mobilization (37). We show 
that cDC ablation induces expression of the CXCR2 ligands CXCL1 
and CXCL2 in the bone marrow. Thus, one potential mechanism 
for the synergistic mobilization with G-CSF is the stimulation of 
CXCR2 signaling in the bone marrow following cDC ablation.
Our data suggest that DCs regulate endothelial cell function 
in the bone marrow. The great majority of bone marrow DCs are 
in direct contact with bone marrow endothelial cells. Ablation of 
cDCs results in endothelial cell expansion and increased vascular 
permeability. Finally, cDC ablation is associated with rapid (with-
in 24 hours) changes in sinusoidal endothelium gene expression, 
suggesting chemokine/cytokine activation and angiogenesis. 
These observations are consistent with prior studies showing that 
cDCs play an important role in inflammatory angiogenesis and 
lymphangiogenesis, possibly through vascular endothelial growth 
factor A (VEGFA) production (38, 39). On the other hand, peri-
vascular macrophages have been implicated in the regulation of 
vascular permeability (40). Interestingly, the increase in vascular 
permeability following cDC ablation was delayed, similar to that 
observed for the loss of bone marrow macrophages. Whether it 
is the loss of macrophages that mediates the increase in vascular 
permeability following cDC ablation will require further study.
We provide evidence that cDC ablation induces HSPC mobili-
zation, in part, by inducing CXCR2 signaling in endothelial cells. 
Following cDC ablation, CXCR2 expression in sinusoidal endo-
thelial cells increases, as does bone marrow expression of the 
CXCR2 ligands CXCL1 and CXCL2. The cellular source of the 
increased CXCL1 and CXCL2 expression and the mechanisms 
for the increased endothelial CXCR2 expression are unclear and 
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In vivo FITC-BSA permeability assay. FITC-conjugated BSA (FITC-
BSA), 0.5 mg in 50 ?l PBS, was intravenously injected into Zbtb46dtr bone 
marrow chimeras, and 15 minutes after injection their femurs were fixed 
and processed for immunostaining. Intravascular FITC-BSA was iden-
tified as an FITC signal that localized inside of VE-cadherin+ blood ves-
sels. Extravascular FITC-BSA was identified as an FITC signal outside 
bone marrow vasculature, but in the bone marrow. Both intravascular 
and extravascular FITC-BSA was quantified using Volocity software. 
Permeability was calculated as: permeability = (extravascular FITC-BSA 
– background) / (intravascular FITC-BSA – background).
Real-time quantitative RT-PCR. Mouse femurs were flushed with 
1 ml TRIzol reagent (Invitrogen) and RNA was isolated according 
to the manufacturer’s instructions. Reverse transcription was per-
formed using the iScript cDNA Synthesis Kit (Bio-Rad) according to 
the manufacturer’s instructions. Quantitative PCR was performed 
using the iTaq Universal Probes Supermix (Bio-Rad) on a StepOne 
Plus Real-Time PCR System (Applied Biosystems). RNA content was 
normalized to mouse ?-actin. Primer and probes for mouse ?-actin 
(Mm01324804_m1), CXCL1 (Mm04207460_m1), and CXCL2 
(Mm00436450_m1) were ordered from Thermo Fisher Scientific.
RNA expression profiling. RNA was purified from sorted dendritic 
cells and endothelial cells using the Qiagen RNeasy Micro Kit (74004, 
Qiagen Technologies). For RNA microarray, libraries were generated 
using the NuGen Pico SL kit (NuGen Technologies) and then hybrid-
ized to Affymetrix Mouse Gene 1.0 ST arrays (Affymetrix). Biotinylat-
ed cDNA was prepared according to the Affymetrix WT Pico reagent 
kit from total RNA. Following fragmentation and labeling, cDNA was 
hybridized onto Affymetrix Clariom S arrays and placed in a GeneChip 
Hybridization Oven 640. GeneChips were then washed and stained in 
an Affymetrix Fluidics Station 450. GeneChips were scanned using 
the Affymetrix GeneChip 7G 3000 Scanner. Data were analyzed on 
an Affymetrix GeneChip Command Console. Microarray expression 
data were processed using the Command Console (Affymetrix) and 
the raw (.CEL) files generated were analyzed using Expression Con-
sole software with Affymetrix default RMA Gene Analysis settings. 
Probe summarization (Robust Multichip Analysis, RMA), quality con-
trol analysis, and probe annotation were performed according to the 
recommended guidelines (Expression Console software, Affymetrix). 
Gene set enrichment was performed using the GSEA software (Broad 
Institute). Heatmap was performed using R package (version 3.4.4).
For RNA sequencing, library preparation was performed with 
1 ng of total RNA using the SMARTer Ultra Low RNA kit for Illumina 
Sequencing (Clontech) per the manufacturer’s protocol. The resulting 
cDNA was fragmented to 150–550 bp using a Covaris E220 sonicator 
(Covaris), then ligated with Illumina sequencing adapters, and ampli-
fied to incorporate unique index tags. Fragments were sequenced on an 
Illumina HiSeq-3000 (Illumina) using single reads extending 50 bases. 
All data from RNA sequencing were analyzed using Partek Flow soft-
ware, version 7.0 (Partek). Reads were aligned to the mm10 mouse ref-
erence genome by STAR (v. 2.5.3a) and normalized FPKM values were 
determined using Partek E/M (mm10 Ensembl Transcripts release 88). 
The Partek gene specific analysis (GSA) algorithm was utilized for dif-
ferential expression analyses. t-SNE plots were performed using Partek.
In vitro permeability test and cell migration assay. HUVECs (S200-
05N, MilliporeSigma) were cultured in Endothelial Cell Growth 
Medium (211-500, MilliporeSigma) at 37°C, 5% CO2. HUVECs (2 × 
105) were precultured in the upper chamber of the Boyden Chamber 
CFU-C assays. Cells obtained from the bone marrow, peripher-
al blood, and spleen were analyzed using a Hemavet automated cell 
counter (Drew Scientific). Peripheral blood (40 ?l), bone marrow cells 
(2.5 × 104), or splenic cells (1.0 × 105 ) were suspended in 3 ml Mouse 
Methylcellulose Complete Media (HSC007, R&D Systems). Cell sus-
pensions were plated in duplicate in 60-mm petri dishes and incubat-
ed in a humidified chamber with 5% CO2 at 37°C. The number of colo-
nies per dish was counted on day 7.
Flow cytometry. Bone marrow, spleen, and peripheral blood were 
processed for flow cytometry as previously described (47). Cells were 
analyzed on a Gallios flow cytometer (Beckman Coulter) or sorted 
using a Sony SY3200 Synergy high-speed cell sorter (Sony). Data anal-
ysis was done using FlowJo version 10.0.7 software (TreeStar). The 
following antibodies were used for staining murine cells: Gr-1 (clone 
RB6-8C5), CD19 (clone 1D3), CD48 (clone BCM1), B220 (clone 
RA3-6B2), CD3e (clone 17A2), Ter119 (clone TER-119), Sca-1 (clone 
D7), CD117 (clone 2B8), CD115 (clone AFS98), CD45 (clone 30-F11), 
CD45.1 (clone A20) and CD45.2 (clone 104), all from eBiosciences; 
CD31 (clone 390), F4/80 (clone BM8), I-A/I-E (clone M5/114.15.2), 
CD11c (clone N418), CD150 (clone TC15-12F12.2), CD169 (clone 
3D6.112), CD11b (clone M1/70), and XCR1 (clone ZET) from BioLeg-
end; and CD71 (clone C2) from BD Biosciences.
For cell sorting, dendritic cells from bone marrow and spleen 
were identified as CX3CR1-GFPhi B220– Gr-1– MHC-IIhi CD11chi cells. 
Sinusoidal endothelial cells were identified as lineage– (CD45– Ter119– 
Gr-1–) CD31+ Sca1– cells, and arteriolar endothelial cells were identi-
fied as lineage– CD31+ Sca1+ cells.
For human bone marrow cells, dendritic cells were identified 
as lineage– (CD3, CD15, CD19, CD20, CD56) CD45+ CD13+ CD14– 
CD33+ CD11c+ HLA-DR+ cells. The following antibodies were used: 
CD3 (clone 555332), CD15 (clone 555401), CD19 (clone 555412), 
CD11c (clone B-ly6), and CD45RA (clone L48) from BD Biosci-
ences; CD13 (clone WM-15), CD20 (clone 2H7), and CD56 (clone 
MEM188) from eBiosciences; CD33 (clone P67.6), CD1c (clone 
L161), CD14 (clone M5E2), CD141 (clone M80), and HLA-DR (clone 
L243) from BioLegend.
Immunostaining of bone sections. Mouse hind limbs were pro-
cessed for immunostaining as previously described (48). The fol-
lowing antibodies were used: chicken anti-GFP (ab13970, Abcam), 
rat anti–MHC-II (107601, BioLegend), rat anti-Sca1 (557403, BD 
Biosciences), goat anti–VE-cadherin (AF1002, R&D Systems), and 
anti-B220 (12-0452-83, eBioscience); Alexa Fluor 488 donkey anti-
rat IgG (Invitrogen), Alexa Fluor 488 donkey anti-chicken IgG (Jack-
son Immunoresearch), and biotin-conjugated donkey anti-goat IgG 
(Jackson Immunoresearch). In some cases, slides were then incubat-
ed with streptavidin-DyLight 649 (Jackson Immunoresearch) for 30 
minutes at room temperature. Finally, slides were mounted with Pro-
Long Gold antifade reagent with DAPI (Life Technologies). Images 
were acquired with an LSM 700 microscope (Carl Zeiss), and images 
were processed using Volocity software (Perkin Elmer).
Histomorphometry was used to quantify the distance of bone 
marrow DCs to the vasculature using CX3CR1-GFP mice. The dis-
tance of GFP-bright reticular-shaped DCs to VE-cadherin+ Sca1– sinu-
soidal endothelial cells or VE-cadherin+ Sca1+ arteriolar endothelial 
cells was quantified using Volocity software (Quorum Technologies). 
Specifically, the distance from the center of the DCs (identified manu-
ally) to the nearest border of the closest endothelial cell was measured.
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Tukey’s Honest Significant Difference post hoc analysis was used to 
evaluate the significance of differences between 2 or multiple groups. 
All data are mean ± SEM.
Study approval. All animal studies were approved by the Institu-
tional Animal Care and Use Committee at Washington University, St. 
Louis, Missouri, USA.
Data availability. RNA expression data for bone marrow DCs and 
the RNA-seq data for sinusoidal endothelial cells have been submitted 
to the Gene Expression Omnibus database (GSE112082, GSE118017, 
respectively).
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system for 24 hours to form a HUVEC layer. During the same time, 
the HUVEC layer was pretreated with 40 ng/ml recombinant CXCL1 
(453-KC-010/CF, Thermo Fisher Scientific) or PBS as a control.
To test permeability of the HUVEC layer, 400 ?l Endothelial Cell 
Growth Medium containing 100 ?g/ml Evans blue was added to the 
upper chamber of the cell insert with 0.4 ?m pores in the membrane 
(141078, Thermo Fisher Scientific). Hank balanced salt solution (1 ml, 
H6648-500ML, MilliporeSigma) was added to the bottom chamber. 
After 1 hour incubation at 37°C, 5% CO2, Evans blue in the bottom 
chamber was measured by light absorbance at 620 nm using an Epoch 
2 microplate spectrophotometer (Biotek), and the amount of Evans 
blue was calculated using a standard curve. Amount of Evans blue 
in the CXCL1-treated samples was normalized to the amount in the 
PBS-treated control samples for comparison.
To test cell migration through the HUVEC layer, 400 ?l medium 
containing approximately 5 × 104 human CD34+ cells was added to 
the upper chamber of the cell insert with 3 ?m pores in the membrane 
(141080, Thermo Fisher Scientific); the bottom chamber contained 
100 ng/ml recombinant CXCL12 (578702, BioLegend). Human 
CD34+ cells were enriched from primary human bone marrow donat-
ed by healthy donors using the CD34 MicroBead Kit (130-100-453, 
Miltenyi Biotec) and autoMACS Pro Separator (Miltenyi Biotec). In 
some cases, the HUVEC layer was treated for 24 hours with CXCL1 
or PBS prior to the addition of CD34+ cells. The number of cells in the 
bottom chamber after a 24-hour incubation at 37°C was quantified 
using a Cellometer Auto T4 Bright Field Cell Counter (Nexcelom).
Statistics. Statistical significance was determined using Prism 6.0 
software (GraphPad). Unpaired t test, 2-way ANOVA, or ANOVA with 
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